Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/11/2025 | $22.00 | Hold | Deutsche Bank |
1/3/2025 | $23.00 → $20.00 | Buy → Neutral | Guggenheim |
10/10/2024 | Mkt Perform | Raymond James | |
8/7/2024 | $28.00 → $20.00 | Overweight → Equal-Weight | Morgan Stanley |
6/27/2024 | $31.00 | Outperform | BMO Capital Markets |
3/12/2024 | $36.00 → $32.00 | Buy | Needham |
3/12/2024 | $39.00 → $25.00 | Buy → Neutral | Mizuho |
1/30/2024 | $40.00 | Outperform | Robert W. Baird |
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that on March 5, 2025, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 71,981 shares of common stock and 42,159 restricted stock units ("RSUs") to thirteen new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $18.08 per share, Acadia's closing trading price on March 5, 2025, and will vest over four years, with 25% of
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will participate in the following virtual investor conferences: UBS Virtual CNS Day 2025 Fireside Chat: Monday, March 17, 2025 at 11:00 a.m. Eastern Time Stifel 2025 Virtual CNS Forum Fireside Chat: Wednesday, March 19, 2025 at 12:30 p.m. Eastern Time 24th Annual Needham Virtual Healthcare Conference Fireside Chat: Monday, April 7, 2025 at 10:15 a.m. Eastern Time Live webcasts of each fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation. About Acadia Pharmaceutic
-- Study supported FDA and Health Canada approvals of DAYBUE for treatment of Rett syndrome in patients ages two years and older -- Results consistent with Phase 3 LAVENDER™ and open-label LILAC™ studies Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE® (trofinetide) in girls ages two to four living with Rett syndrome (n = 15). The long-term Phase 2/3 study demonstrated DAYBUE had a similar safety profile in children two to four years of age as that observed in individuals with Rett syndrome five years of age and older in the 12-week
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)
NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE:SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Jan 3, 2025 S&P SmallCap 600 Addition Acadia Pharmaceuticals ACAD Health Care Jan 3, 2025 S&P SmallCap 600 Deletion Independent Bank Group
– Seasoned commercial executive with more than 25 years pharmaceutical and biotech experience Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia's commercial strategy and operations, driving the Company's plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia's CEO, and serve on the executive leadership team. "Tom is an accomplished commercial executive with a demonstrated history of driving brand growth across a wide range of therapeutic areas
- Ms. Owen Adams brings over 25 years of pharmaceutical industry experience including senior commercial leadership roles with Bristol Myers Squibb and Johnson & Johnson Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive Officer (CEO) and joined the Acadia Board of Directors. "We are excited to welcome Catherine Owen Adams as the new CEO of Acadia," said Stephen Biggar, M.D., Ph.D., Chair of the Board of Directors. "Catherine is a proven global leader with a distinguished record of accomplishment of driving growth and innovation in the pharmaceutical industry. Her strategic vision, deep expertise, and unwavering
Deutsche Bank initiated coverage of ACADIA Pharmaceuticals with a rating of Hold and set a new price target of $22.00
Guggenheim downgraded ACADIA Pharmaceuticals from Buy to Neutral and set a new price target of $20.00 from $23.00 previously
Raymond James resumed coverage of ACADIA Pharmaceuticals with a rating of Mkt Perform
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
SC 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy
Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity
- 2024 total net product sales of $957.8 million, reflecting 32% revenue growth - Fourth quarter DAYBUE® (trofinetide) net product sales of $96.7 million and full year 2024 net product sales of $348.4 million - Fourth quarter NUPLAZID® (pimavanserin) net product sales of $162.9 million and full year 2024 net product sales of $609.4 million - Full year 2025 total revenue guidance of $1.03 to $1.095 billion including DAYBUE net sales guidance of $380 to $405 million and NUPLAZID net sales guidance of $650 to $690 million Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. "We closed 2024 on a s
Company to host conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on February 26, 2025, at 4:30 p.m. Eastern Time. The webcast will be available on Acadia's website, Acadia.com under the investors section and will be archived there until May 26, 2025. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email
- 3Q24 total revenues of $250.4 million, up 18% year-over-year - 3Q24 NUPLAZID® (pimavanserin) net product sales of $159.2 million, up 10% year-over-year - 3Q24 DAYBUE™ (trofinetide) net product sales of $91.2 million, up 36% year-over-year Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced its financial results for the third quarter ended September 30, 2024. "The success of Acadia's two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive milestone of more than $1 billion in annualized sales in 2025," said Catherine Owen Adams, Chief Executive Officer.
10-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)
8-K - ACADIA PHARMACEUTICALS INC (0001070494) (Filer)